{"id":569667,"date":"2026-10-07T15:00:00","date_gmt":"2026-10-07T13:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/sglt-2-inhibitor-and-or-incretin-mimetic-as-an-add-on\/"},"modified":"2026-10-12T16:49:07","modified_gmt":"2026-10-12T14:49:07","slug":"sglt-2-inhibitor-and-or-incretin-mimetic-as-an-add-on","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/sglt-2-inhibitor-and-or-incretin-mimetic-as-an-add-on\/","title":{"rendered":"SGLT-2 inhibitor and\/or incretin mimetic as an add-on?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nowadays, the choice of drug therapy is no longer based solely on the<sub>baseline HbA1c level<\/sub>, but also on risk factors or comorbidities such as heart failure, kidney disease, or obesity. Due to their additional cardiorenal benefits, SGLT-2 inhibitors or incretin mimetics are recommended as add-ons to metformin for many people with type 2 diabetes. Furthermore, it has been shown that additive effects can be achieved by combining SGLT-2 inhibitors and incretin mimetics. The fact that a dual GLP-1\/GIP agonist has now also become established in clinical practice represents a further optimization of treatment options.<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fsglt-2-inhibitor-and-or-incretin-mimetic-as-an-add-on%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Nowadays, the choice of drug therapy is no longer based solely on thebaseline HbA1c level, but also on risk factors or comorbidities such as heart failure, kidney disease, or obesity.&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fsglt-2-inhibitor-and-or-incretin-mimetic-as-an-add-on%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":569669,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Type 2 Diabetes: From a Glucocentric to a Cardiorenal-Metabolic Approach","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11548,11359,11513,11508,11384,11413,11503],"tags":[102729,23427,44110,20717,18546,102728,36829,12130,102726,94778,21430,11659,12390,94780,23857,73042,17444,18549,72410,12042,77169],"powerkit_post_featured":[],"class_list":["post-569667","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-cardiology","category-congress-reports","category-education","category-endocrinology-and-diabetology","category-nephrology","category-studies","tag-cardiorenal-added-benefit","tag-dapagliflozin-en","tag-empagliflozin-en","tag-forxiga-en","tag-glp-1-receptor-agonist","tag-glp-1-gip-agonist","tag-hba1c-en","tag-heart-failure-en","tag-incretin-mimetic","tag-jardiance","tag-kidney-disease","tag-metformin-en","tag-obesity","tag-ozempic","tag-risk-factors","tag-rybelsus-en","tag-semaglutide-en-2","tag-sglt-2-i-en","tag-tirzepatide","tag-type-2-diabetes","tag-wegovy-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-21 15:04:34","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":569744,"slug":"un-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint","post_title":"Un inhibiteur de la SGLT-2 et\/ou un mim\u00e9tique de l'incr\u00e9tine en traitement d'appoint ?","href":"https:\/\/medizinonline.com\/fr\/un-inhibiteur-de-la-sglt-2-et-ou-un-mimetique-de-lincretine-en-traitement-dappoint\/"},"it_IT":{"locale":"it_IT","id":569673,"slug":"un-farmaco-della-classe-sglt-2-e-o-un-mimico-dellincretina-come-terapia-aggiuntiva","post_title":"Un farmaco della classe SGLT-2 e\/o un mimico dell\u2019incretina come terapia aggiuntiva?","href":"https:\/\/medizinonline.com\/it\/un-farmaco-della-classe-sglt-2-e-o-un-mimico-dellincretina-come-terapia-aggiuntiva\/"},"pt_PT":{"locale":"pt_PT","id":569679,"slug":"um-inibidor-da-sglt-2-e-ou-um-mimetico-da-incretina-como-tratamento-complementar","post_title":"Um inibidor da SGLT-2 e\/ou um mim\u00e9tico da incretina como tratamento complementar?","href":"https:\/\/medizinonline.com\/pt-pt\/um-inibidor-da-sglt-2-e-ou-um-mimetico-da-incretina-como-tratamento-complementar\/"},"es_ES":{"locale":"es_ES","id":569749,"slug":"un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario","post_title":"\u00bfUn inhibidor de SGLT-2 y\/o un mim\u00e9tico de la incretina como tratamiento complementario?","href":"https:\/\/medizinonline.com\/es\/un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/569667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=569667"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/569667\/revisions"}],"predecessor-version":[{"id":569670,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/569667\/revisions\/569670"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/569669"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=569667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=569667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=569667"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=569667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}